nesuparib (JPI-547) / Jeil  >>  Phase 1
Welcome,         Profile    Billing    Logout  

2 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
nesuparib (JPI-547) / Jeil
NCT04335604: A Study of NOV140201 (JPI-547) in Subject With Advanced Solid Tumors

Completed
1
62
RoW
JPI-547
Onconic Therapeutics Inc., Jeil Pharmaceutical Co., Ltd.
Advanced Solid Tumors
12/21
12/21
NCT05257993: Study to Assess the Safety, Tolerability of JPI-547 in Combination With Modified FOLFIRINOX or Gemcitabine-nab-paclitaxel in Patients With Locally Advanced and Metastatic Pancreatic Cancer

Not yet recruiting
1
24
NA
JPI-547, modified FOLFIRINOX, Gemcitabine-nab-paclitaxel
Onconic Therapeutics Inc.
Pancreatic Ductal Adenocarcinoma
08/23
08/23

Download Options